IRVING, Texas , Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced a partnership with Everlywell, a digital health company pioneering the next generation of biomarker intelligence, combining AI-powered technology with human insight to deliver personalized, actionable health answers. 

Caris and Everlywell are partnering to launch Caris Detect™, Caris' forthcoming Multi-Cancer Early Detection (MCED) blood-based screening assay, through Everlywell's platform. Caris Detect utilizes comprehensive whole genome sequencing (WGS) technology to identify multiple cancer types by analyzing molecular signals circulating in the bloodstream.

"Caris Life Sciences is proud to partner with Everlywell to expand access to Caris Detect, Caris' revolutionary MCED assay driven by WGS technology," said Caris President David Spetzler, MS, PhD, MBA. "By combining our advanced precision medicine technologies with Everlywell's consumer-focused platform, we're creating a powerful new pathway for people to detect cancer at its earliest and most treatable stages, before it can spread, ultimately supporting better outcomes for patients."

"Our partnership with Caris Life Sciences will enhance access to Caris Detect testing, which represents a powerful step forward in how cancer is identified earlier and more proactively," said Julia Cheek, Founder and CEO, Everlywell. "Everlywell has spent the last decade defining the standard for accessible diagnostics. By combining our consumer reach, established infrastructure, and clinical leadership, we are uniquely positioned to bring this transformational technology to people across the country."

Caris expects to launch the Caris Detect assay in the first half of 2026.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. 

Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. 

About Everlywell
Everlywell is a digital health company pioneering the next generation of biomarker intelligence—combining AI-powered technology with human insight to deliver personalized, actionable health answers. Everlywell transforms complex biomarker data into life-changing insights, seamlessly integrating advanced diagnostics, virtual care, and patient engagement to reshape how and where health happens. Over the past decade, Everlywell has delivered nearly 1 billion personalized health insights, transformed care for 60 million people and powered hundreds of enterprise partners, including 4 of the 5 largest health plans in the U.S. that cover 170 million insured lives. Fueled by AI and built for scale, Everlywell is breaking down barriers, closing care gaps, and unlocking a more connected healthcare experience that is smarter, faster, and more personalized. Learn more at everlywell.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, launch timing, performance, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.   

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Quarterly Report on Form 10-Q filed on or about November 5, 2025, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. 

Caris Life Sciences Media:  
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-partners-with-everlywell-to-launch-caris-forthcoming-mced-assay-caris-detect-302657803.html

SOURCE Caris Life Sciences